Development

Epigenetic editing reaches clinical testing for hepatitis B

The reported intervention targets gene activity rather than cutting the DNA sequence.

development2026-09-22biotech

Claim

The newsletter reports clinical use of epigenetic editing to silence hepatitis B DNA through methylation rather than DNA cutting.

Reporting date: 2026-09-22 (not necessarily the event date)

Sources

Attribution and reporting linked by this record; links do not imply independent verification.

Welcome to September 22, 2026 (theinnermostloop.substack.com)
Source linked by the September 22 issue (www.nature.com)

Indexed from the September 22 newsletter. Linked-source claims have not been independently verified.

Knowledge graphopen in browser →

Reported in

Welcome to September 22, 2026

Referenced by

Welcome to September 22, 2026

Cite or correct this record

Citation formatCitation text

Epigenetic editing reaches clinical testing for hepatitis B
Innermost Loop KB — secondary record
Reporting date: 2026-09-22
KB permalink: https://nicholsn.github.io/innermost-loop-kb/developments/2026-09-22-epigenetic-clinic
Claim: The newsletter reports clinical use of epigenetic editing to silence hepatitis B DNA through methylation rather than DNA cutting.
Attributed sources:
- Welcome to September 22, 2026 — https://theinnermostloop.substack.com/p/welcome-to-september-22-2026
- Source linked by the September 22 issue — https://www.nature.com/articles/d41586-026-02981-9
This citation does not imply independent verification of linked-source claims.

Suggest a correction — opens a GitHub draft for you to review and submit.